# Medical Oncology (genitourinary) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pablo Neruda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML051-SYN
- Date: 2026-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Étienne Okonkwo-Lund, MD
- Calendar frame: modern shifted

- Requested by: Marisol Fairweather-Diaz, MD

## Reason for consultation

Man of 66 with four months of urinary symptoms and six weeks of right hip and low back pain, a hard nodular prostate, PSA 46.8 ng/mL and a raised alkaline phosphatase: suspected metastatic prostate cancer. Please confirm the diagnosis and extent and advise on treatment, including bone health and genetic testing. **S**

## History

Mr. Neruda is seen at the request of Dr. Fairweather-Diaz, with a professional Spanish interpreter, for suspected metastatic prostate cancer. He has had four months of urinary frequency, a weak stream and nocturia, and six weeks of right hip and low back pain, now 5 of 10 on acetaminophen. He has no leg weakness, numbness, or change in bladder or bowel control, and no weight loss. He has hypertension treated with amlodipine and no other illness. He never smoked. Beyond his mother's death shortly after his birth, he does not know his family's medical history. He is fully active apart from the hip pain (ECOG 1), writes every morning and carries a full schedule of official duties. He asked for a plain account of the results and of every option. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; walks without help, favoring the right hip slightly; ECOG 1 |
| Musculoskeletal | Tender over the right iliac crest; no midline spinal tenderness |
| Neurological | Strength 5 of 5 in both legs; sensation and reflexes normal |
| Lymph nodes | No inguinal or supraclavicular nodes |

BP 142/86 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 92 kg; BMI 29 kg/m². All vital signs are synthetic.

## Data reviewed

Multiparametric MRI of the prostate (52 mL gland; 24 mm PI-RADS 5 right peripheral zone lesion with extraprostatic extension; 13 mm right external iliac node); MRI-targeted biopsy (Gleason 4+4, Grade Group 4, in 9 of 14 cores, all on the right, with perineural invasion); CT of the chest, abdomen and pelvis (right external iliac 13 mm and obturator 11 mm nodes; sclerotic lesions in the right iliac wing and L5 without canal narrowing; no visceral disease); bone scan (two lesions only, right ilium and L5); gallium-68 PSMA PET/CT (concordant, no further disease); the first-visit laboratory tests; and this morning's DXA (femoral neck T-score -2.1, L1 to L4 -1.4). Femoral neck T-score (DXA): -2.1 (low); Lumbar spine T-score, L1 to L4 (DXA): -1.4 (low); PHQ-2: 1; Pain, 0 to 10: 5. All results are synthetic.

## Assessment

1. **Prostate adenocarcinoma, Grade Group 4, cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume** (C61). The diagnosis is confirmed. By the conventional-imaging definition used in the trials and the AUA/SUO guideline, high volume means four or more bone metastases with at least one outside the spine and pelvis, or visceral metastases; he has two bone metastases, both within the spine and pelvis, and no visceral disease, so the disease is low volume. The PSMA PET/CT shows nothing more. He has symptoms from the bone metastasis in the right ilium. **S**
2. **Systemic treatment** (Z79.899). Androgen deprivation should be combined with an androgen receptor pathway inhibitor. Apalutamide, enzalutamide, darolutamide and abiraterone with prednisone are all reasonable. Apalutamide is a single daily tablet without a steroid and improved survival in low-volume disease in the TITAN trial; abiraterone needs prednisone and can worsen blood pressure and glucose, which matters with his hypertension and prediabetes. Docetaxel is not recommended: in low-volume disease it did not clearly improve survival, and triplet therapy is reserved for selected patients with high-volume disease. Apalutamide started a week before the first leuprolide injection also blocks the testosterone flare, so bicalutamide is not needed. **S**
3. **Radiotherapy to the prostate**. In low-volume metastatic disease, radiotherapy to the prostate added to androgen deprivation improved survival in STAMPEDE, and the guidelines support it in selected patients. It is recommended, about six weeks after starting androgen deprivation, as 55 Gy in 20 daily fractions. **S**
4. **Bone health and bone metastases** (M85.89). Bone-protective drugs at the monthly doses used to prevent skeletal events are recommended in castration-resistant disease; in hormone-sensitive disease, early zoledronic acid did not reduce skeletal events (CALGB 90202). His own fracture risk is the reason to treat: FRAX with androgen deprivation counted gives a hip fracture risk of 3.4 percent, above the 3 percent threshold. Denosumab 60 mg every six months, the osteoporosis dose, is recommended after a dental examination and once vitamin D replacement has begun and calcium is normal. The painful iliac metastasis is likely to settle on androgen deprivation; radiotherapy to that bone remains an option if it does not. **S**
5. **Genetic testing**. Germline testing is recommended for every patient with metastatic prostate cancer, and somatic testing of the tumor for metastatic disease; the results could change later treatment (a PARP inhibitor for a BRCA2 alteration) and would matter for his relatives. Pre-test counseling was done today. **S**
6. **Drug interactions and hypertension** (I10). Apalutamide is a strong CYP3A4 inducer and will lower amlodipine levels, so blood pressure may rise in the first weeks. It also raises the risk of rash, falls, fractures and raised TSH. **S**

## Recommendations

1. Apalutamide 240 mg once daily, starting today.
2. Leuprolide 22.5 mg intramuscularly in one week at this clinic, then every twelve weeks, continuously.
3. No docetaxel for low-volume disease.
4. Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation; radiation oncology planning in about four weeks.
5. Germline testing sent today after counseling; somatic testing on the biopsy tissue.
6. Bone health: cholecalciferol 2000 units daily, calcium 1000 to 1200 mg a day from food, weight-bearing and resistance exercise, a dental examination, then denosumab 60 mg every six months; DXA every one to two years.
7. Acetaminophen for pain; same-day assessment for new leg weakness or numbness or loss of bladder or bowel control.
8. Primary care monitoring: blood pressure at every visit, with the amlodipine dose adjusted as needed; PSA and testosterone at about four weeks and three months, then every three months; blood count and chemistry; TSH before apalutamide and every four months; hemoglobin A1c and lipids at baseline and yearly; rash, falls, hot flashes, fatigue, sexual health, mood and cognition at each visit.
9. Report any rash early: grade 1 or 2 rash is treated with a topical steroid and an antihistamine while apalutamide continues; apalutamide is held for grade 3 rash or any blistering or mucosal involvement.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Fairweather-Diaz today. The plan was explained in Spanish through a professional interpreter, with a written summary in Spanish. Mr. Neruda chose apalutamide with leuprolide and radiotherapy to the prostate after hearing each option, including docetaxel and abiraterone, and agrees with the plan. **S**

## Follow-up

Leuprolide injection here in one week. Radiation oncology planning in about four weeks. Medical oncology review at three months with PSA and testosterone, and every three months after that. Primary care sees him at four weeks for blood pressure, the early PSA and the first denosumab dose, and carries out the monitoring above between oncology visits. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026), American Urological Association and Society of Urologic Oncology
- Chi KN, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer (TITAN). N Engl J Med 2019;381(1):13-24 (2019), New England Journal of Medicine
- Kyriakopoulos CE, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2018;36(11):1080-1087 (2018), Journal of Clinical Oncology
- Parker CC, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353-2366 (2018), The Lancet
- Smith MR, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2014;32(11):1143-1150 (2014), Journal of Clinical Oncology
- ERLEADA (apalutamide) tablets: prescribing information (2026), Janssen Products, LP, via DailyMed (National Library of Medicine)
- CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026), Aether Forge
